Tumour growth is accompanied by tumour evasion of the immune system, a process that is
facilitated by immune checkpoint molecules such as programmed cell death protein 1 (PD1) …

Decades of research have disclosed a plethora of alterations in protein glycosylation that
decisively impact in all stages of disease and ultimately contribute to more aggressive cell …

Currently approved immune checkpoint inhibitor therapies targeting the PD-1 and CTLA-4
receptor pathways are powerful treatment options for certain cancers; however, most …

Abstract Changes in glycosylation during tumour progression are a key hallmark of cancer.
One of the glycan moieties generally overexpressed in cancer are sialic acids, which can …

Glioblastoma (GBM) is the most aggressive form of primary brain tumor, for which effective
therapies are urgently needed. Cancer cells are capable of evading clearance by …

Simple Summary All cells are covered in a thick layer of sugar molecules known as glycans.
Changes to this sugar coat are common in cancer, and in particular cancer cells often …

Aberrant glycosylation plays a fundamental role in key pathological steps of tumour
development and progression. Glycans have roles in cancer cell signalling, tumour cell …

Cell-cell interactions and cell adhesion are key mediators of cancer progression and
facilitate hallmarks of cancer including immune evasion and metastatic dissemination. Many …

First-generation immune checkpoint inhibitors, including anti–CTLA-4 and anti–programmed
death 1 (anti–PD-1) antibodies, have led to major clinical progress, yet resistance frequently …

Protein posttranslational modifications (PTMs) refer to the breaking or generation of covalent
bonds on the backbones or amino acid side chains of proteins and expand the diversity of …